Melanotan II and peptide 'poison' claims: what the evidence shows

What did @tattedpoet actually say?

The creator made a sweeping claim: Melanotan II is "poison" that was abandoned in clinical trials because of dangerous side effects, while Melanotan I (afamelanotide) is a safe, approved alternative that delivers tanning benefits without the risks. They said MT-2 is a "multi-receptor antagonist" that raises blood pressure, crosses the blood-brain barrier, causes anxiety, and disrupts male hormones. They positioned MT-1 as the responsible upgrade.

To be fair, they added a disclaimer: not a doctor, not medical advice, general information only. That caveat does not, however, change the impact of a 68,000-view video telling people a widely-used peptide is poison and offering a named alternative.

Does the science back this up?

Partially, and that partial credit matters less than the gaps. MT-2 does have a broader receptor binding profile than MT-1, and the trial record does show it was not approved. But calling it outright "poison" overstates what the data shows, and the framing of MT-1 as a clean, accessible alternative misses critical regulatory and safety context.

Melanotan II is a non-selective melanocortin receptor agonist, binding MC1R through MC5R. The MC3R and MC4R activity is where the cardiovascular and sexual side effects come from. That is documented. A 2003 paper by van der Ploeg et al. in the European Journal of Pharmacology described MC4R agonism producing erectile effects and cardiovascular changes in animal models. Human studies have confirmed nausea, flushing, spontaneous erections, and blood pressure changes. So the creator is not fabricating those side effects.

However, "they dropped it due to all the side effects" is an oversimplification. MT-2 was never formally submitted for FDA approval as a finished pharmaceutical product. It stalled at investigational stages for multiple reasons, including commercial prioritization of afamelanotide, not exclusively because it was deemed too toxic to develop.

What did they get wrong (or right)?

They got the receptor pharmacology directionally right but dressed it in language that is more alarming than the published evidence supports. Calling MT-2 a "multi-receptor antagonist" is actually incorrect terminology. It is an agonist, not an antagonist. An antagonist blocks a receptor. MT-2 activates multiple receptors. That is a meaningful pharmacological distinction, not a nitpick.

On MT-1, the creator said it "was approved during clinical trials" and "is an approved medication in multiple countries." This is accurate but incomplete in a way that could mislead viewers. Afamelanotide (Scenesse) is approved in the EU and the US, but specifically for erythropoietic protoporphyria, a rare genetic disorder. It is administered as a subcutaneous implant by a clinician, not a self-injectable peptide you order online. The implication that people can simply switch from black-market MT-2 to MT-1 as a safer tanning option glosses over the fact that the approved version is not available as a consumer product.

• Correct: MT-2 has documented cardiovascular and CNS side effects linked to off-target receptor activity.
• Correct: Afamelanotide has an established clinical trial record and regulatory approval.
• Incorrect: MT-2 is an agonist, not an antagonist.
• Misleading: Framing MT-1 as a readily available safer swap ignores that approved afamelanotide is a prescription implant for a rare disease, not a tanning aid people can self-administer.

What should you actually know?

Both MT-1 and MT-2 exist in a gray-to-black market as research chemicals. Neither is legally available as a self-administered tanning product in the US. The MT-2 you encounter online is not pharmaceutical grade, carries no quality controls, and the dosing free-for-all on forums like Reddit and various peptide communities is genuinely risky. That part of the creator's concern is valid.

But the solution is not to swap to a different unregulated peptide and call it safe. Afamelanotide's safety profile in clinical settings, under medical supervision, with controlled dosing, does not automatically transfer to a vial of unknown purity bought from a gray-market vendor. A 2015 study by Harms et al. in the British Journal of Dermatology noted that unsupervised use of melanocortin peptides raises legitimate concerns about melanoma risk, given that accelerated melanogenesis without UV exposure could theoretically activate dormant nevi. That research is not settled, but it is a real open question the creator did not mention.

If you are genuinely photosensitive or exploring peptide therapy, that conversation belongs with a licensed clinician who can assess your full health picture, not a TikTok comment section.